Skip to main content

Year: 2025

onsemi Reports Third Quarter 2025 Results

Results exceed expectations Scottsdale, Ariz, Nov. 03, 2025 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its third quarter 2025 results with the following highlights:Revenue of $1,550.9 millionGAAP gross margin of 37.9% and non-GAAP gross margin of 38.0%GAAP operating margin of 17.0% and non-GAAP operating margin of 19.2%GAAP diluted earnings per share and non-GAAP diluted earnings per share of $0.63Cash from operations of $418.7 millionFree cash flow of $372.4 million grew 22% year-over-year to 24% of revenue Year-to-date share repurchases of $925 million, approximately 100% of free cash flow“Our third quarter results exceeded expectations, underscoring the strength of our strategy and the resilience of our business model. We’re seeing continued signs of stabilization across our core...

Continue reading

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

At 24 months, the target lesion primary patency (TLPP)1 was 41.7% At 24 months, the access circuit primary patency (ACPP)2 was 25.7%SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV. For the millions of patients diagnosed with advanced kidney disease, hemodialysis is a life-saving treatment that replaces the function of the kidneys. The administration of hemodialysis requires ongoing vascular access (access to blood vessels) that is commonly...

Continue reading

The new shares subscribed for in Aspocomp Group Plc’s Directed Share Issue have been registered with the Trade Register

Aspocomp Group Plc, Stock Exchange Release, November 3, 2025 at 4:20 p.m. The new shares subscribed for in Aspocomp Group Plc’s directed share issue have been registered with the Trade Register. A total of 673,682 new shares subscribed for in Aspocomp’s Directed Share Issue have been registered with the Finnish Trade Register on October 31, 2025. After the registration of the new shares, the total number of shares in the company is 7,522,922 shares. The new shares will confer equal rights to the company’s existing shares from the date of registration. The new shares will be admitted to trading on Nasdaq Helsinki Ltd’s main list approximately from November 4, 2025 onwards. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. ASPOCOMP GROUP PLC Manu SkyttäPresident and...

Continue reading

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program; on-track for IND in 2026 WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced three presentations featuring bezuclastinib, including two oral presentations in NonAdvanced Systemic Mastocytosis (NonAdvSM), at the 67th Annual Meeting of the American Society of Hematology (ASH) being held December 6-9, 2025 in Orlando, FL. Cogent also announced today plans to describe its novel JAK2 V617F mutant-selective inhibitor as part of a poster presentation...

Continue reading

JAKKS Pacific and SEGA of America Renew Global Toy Partnership for Sonic the Hedgehog™ Merchandise

JAKKS x SEGA RenewalJAKKS Pacific, Inc. (NASDAQ: JAKK) today announced a partnership renewal with SEGA of America, Inc. (“SEGA®”) for the core the Sonic the Hedgehog Collection, maintaining JAKKS as the franchise’s lead global toy partner.SANTA MONICA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (NASDAQ: JAKK) today announced a partnership renewal with SEGA of America, Inc. (“SEGA®”) for the core the Sonic the Hedgehog Collection, maintaining JAKKS as the franchise’s lead global toy partner. JAKKS will continue to design, manufacture, market, and sell Sonic the Hedgehog branded toy product lines worldwide. This multi-year partnership extends until 2029, allowing JAKKs to continue to design and produce action figures, playsets, vehicles, plush, collectibles, and other categories. The JAKKS line of Sonic...

Continue reading

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia. In addition to these clinical presentations, Nurix...

Continue reading

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Ronde-cel is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate, currently in pivotal development for the treatment of LBCL, that is designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell...

Continue reading

IPSIPAY to launch next-generation Crypto Payment Platform

LAS VEGAS, Nov. 03, 2025 (GLOBE NEWSWIRE) — Innovative Payment Solutions, Inc. (Trading Symbol ‘IPSI’ on OTCID), a provider of digital payment and fintech solutions, today announced the launch of its next-generation Crypto Payment Platform, designed to provide IPSI’s clients including those in online gaming, iGaming, and sportsbook sectors with seamless, compliant, and secure cryptocurrency payment capabilities. This new platform enables operators to accept and process digital assets such as Bitcoin, Ethereum, USDC, and other major cryptocurrencies in real time, while offering automatic conversion to fiat currencies and full integration with existing IPSI merchant services. Transforming Digital Commerce into Gaming and Beyond The IPSI Crypto Payment Platform bridges the gap between traditional and decentralized finance (DeFi) by...

Continue reading

Turnover of Apranga Group in October 2025

The retail turnover (including VAT) of the Apranga Group amounted to EUR 34.7 million in October 2025 and increased by 4.9% compared to October 2024. The retail turnover (including VAT) of Apranga Group reached EUR 300.5 million in January-October 2025 and increased by 5.6% compared to the corresponding period of 2024. In January-October 2025, the retail turnover of Apranga Group in Lithuania increased by 7.5% year-to-year, in Latvia increased by 5.4% and decreased by -1.3% in Estonia. Currently Apranga Group operates the chain of 171 stores (103 in Lithuania, 44 in Latvia and 24 in Estonia) covering the gross area of 92.7 thousand sq. m., or by 0.8% more than a year ago. Rimantas Perveneckas„Apranga“ Group General Manager+370 5 2390801

Continue reading

Nokia and Rohde & Schwarz collaborate on AI-powered 6G receiver to cut costs, accelerate time to market

Press ReleaseNokia and Rohde & Schwarz collaborate on AI-powered 6G receiver to cut costs, accelerate time to marketAI-powered receiver technology using machine learning can greatly enhance future 6G coverage, creating cost savings and accelerating time to market. The AI technology identifies and compensates for distortion in wireless signals, leading to substantial improvements in 6G uplink coverage. Nokia and Rohde & Schwarz will demonstrate the technology at the Brooklyn 6G Summit from November 5-7.3 November 2025Espoo, Finland – Nokia and the test and measurement company Rohde & Schwarz have created and successfully tested a 6G radio receiver that uses AI technologies to overcome one of the biggest anticipated challenges of 6G network rollouts, coverage limitations inherent in 6G’s higher-frequency spectrum. The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.